UY38069A - Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico - Google Patents

Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Info

Publication number
UY38069A
UY38069A UY38069A UY38069A UY38069A UY 38069 A UY38069 A UY 38069A UY 38069 A UY38069 A UY 38069A UY 38069 A UY38069 A UY 38069A UY 38069 A UY38069 A UY 38069A
Authority
UY
Uruguay
Prior art keywords
relaxin
lipided
modified
therapeutic use
chain peptides
Prior art date
Application number
UY38069A
Other languages
English (en)
Inventor
Illiano Stéphane
Sergio Mallart
Minoletti-Hochepied Claire
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Olivier Duclos
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY38069A publication Critical patent/UY38069A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido de Relaxina monocatenario biológicamente activo que tiene la siguiente fórmula (I): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter o una sal o solvato de este. También trata sobre una composición farmacéutica que comprende al menos un péptido de la invención, y el péptido o la composición farmacéutica para su uso como medicamento.
UY38069A 2018-01-31 2019-01-31 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico UY38069A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31

Publications (1)

Publication Number Publication Date
UY38069A true UY38069A (es) 2019-08-30

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
UY38069A UY38069A (es) 2018-01-31 2019-01-31 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Country Status (18)

Country Link
US (3) US10961295B2 (es)
EP (1) EP3746467A1 (es)
JP (1) JP7295871B2 (es)
KR (1) KR20200116085A (es)
CN (1) CN111770934A (es)
AR (1) AR114325A1 (es)
AU (1) AU2019214358B2 (es)
BR (1) BR112020014834A2 (es)
CA (1) CA3089657A1 (es)
CO (1) CO2020008308A2 (es)
IL (1) IL276170A (es)
MA (1) MA52994A (es)
MX (1) MX2020008096A (es)
PH (1) PH12020551118A1 (es)
SG (1) SG11202006903WA (es)
TW (1) TWI763972B (es)
UY (1) UY38069A (es)
WO (1) WO2019149782A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102670432B1 (ko) 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
BR112020014834A2 (pt) 2018-01-31 2020-12-08 Sanofi Peptídeos de cadeia b de relaxina lipidada modificada e seu uso terapêutico
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4392440A2 (en) * 2021-08-23 2024-07-03 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2745499A1 (en) * 2008-12-05 2010-06-10 Angiochem Inc. Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
KR20140054009A (ko) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
JP6276690B2 (ja) * 2011-08-04 2018-02-07 ファリス バイオテック ゲーエムベーハー ヒトリラキシン−２を調製する方法
US20160152679A1 (en) * 2012-05-24 2016-06-02 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
KR102302634B1 (ko) * 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
WO2015162485A1 (en) * 2014-04-22 2015-10-29 Txp Pharma Gmbh Peptide analogues with branched amino acid probe(s)
KR102670432B1 (ko) * 2017-02-08 2024-05-28 브리스톨-마이어스 스큅 컴퍼니 약동학적 인핸서를 포함하는 변형된 렐락신 폴리펩티드 및 그의 용도
WO2019149781A1 (en) 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TW201934572A (zh) 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
BR112020014834A2 (pt) 2018-01-31 2020-12-08 Sanofi Peptídeos de cadeia b de relaxina lipidada modificada e seu uso terapêutico
CN114174348A (zh) * 2019-07-31 2022-03-11 伊莱利利公司 胰岛素类似物及其使用方法

Also Published As

Publication number Publication date
AU2019214358A1 (en) 2020-08-20
US20240218042A1 (en) 2024-07-04
AU2019214358B2 (en) 2023-05-25
US11725036B2 (en) 2023-08-15
BR112020014834A2 (pt) 2020-12-08
EP3746467A1 (en) 2020-12-09
CO2020008308A2 (es) 2020-10-30
SG11202006903WA (en) 2020-08-28
RU2020126210A (ru) 2022-02-28
AR114325A1 (es) 2020-08-19
IL276170A (en) 2020-09-30
MA52994A (fr) 2021-05-05
PH12020551118A1 (en) 2021-07-05
US20210292387A1 (en) 2021-09-23
CA3089657A1 (en) 2019-08-08
JP7295871B2 (ja) 2023-06-21
TW201940505A (zh) 2019-10-16
CN111770934A (zh) 2020-10-13
US10961295B2 (en) 2021-03-30
TWI763972B (zh) 2022-05-11
WO2019149782A1 (en) 2019-08-08
JP2021512099A (ja) 2021-05-13
MX2020008096A (es) 2020-09-24
KR20200116085A (ko) 2020-10-08
US20190233494A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
UY38069A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2619322T3 (es) Agente inductor de inmunidad
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
BR112018003898A2 (pt) material auxiliar para aplicação no tecido de cólon
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CU23734A1 (es) Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
PE20210116A1 (es) Administracion oral de analogos del peptido glp-1
BR112022007718A2 (pt) Composição farmacêutica, e, métodos de tratamento de um sujeito em necessidade e para produção de uma composição farmacêutica sólida
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
CL2017003201A1 (es) Variantes de il-37

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240513